Published in Clin Cancer Res on December 15, 2009
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis (2010) 1.95
Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res (2013) 1.75
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol (2013) 1.71
Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics (2010) 1.57
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov (2012) 1.49
Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell (2013) 1.44
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 1.39
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell (2013) 1.29
Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One (2012) 1.25
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int (2012) 1.24
Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer (2012) 1.23
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. PLoS One (2012) 1.16
PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia (2013) 1.11
Shortening of 3'UTRs correlates with poor prognosis in breast and lung cancer. PLoS One (2012) 1.08
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Gene expression differences between colon and rectum tumors. Clin Cancer Res (2011) 1.03
RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol (2015) 1.03
Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature. Int J Colorectal Dis (2012) 1.01
Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer. Br J Cancer (2013) 0.99
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res (2014) 0.99
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res (2012) 0.96
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist (2015) 0.95
5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer. Genome Biol (2015) 0.93
CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One (2013) 0.91
Signal propagation in protein interaction network during colorectal cancer progression. Biomed Res Int (2013) 0.91
Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Mol Med (2015) 0.91
Comparison of prognostic genomic predictors in colorectal cancer. PLoS One (2013) 0.90
DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol (2012) 0.88
Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. BMC Cancer (2014) 0.86
Nuclear localization of γ-tubulin affects E2F transcriptional activity and S-phase progression. FASEB J (2011) 0.86
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J Zhejiang Univ Sci B (2012) 0.85
Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One (2015) 0.84
Empowering biologists with multi-omics data: colorectal cancer as a paradigm. Bioinformatics (2014) 0.84
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. Br J Cancer (2014) 0.84
Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications. Microarrays (Basel) (2015) 0.84
A feature selection method for classification within functional genomics experiments based on the proportional overlapping score. BMC Bioinformatics (2014) 0.84
AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget (2014) 0.84
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. Oncotarget (2015) 0.83
An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer (2010) 0.83
A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clin Cancer Res (2015) 0.83
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival. Oncotarget (2015) 0.83
Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers (Basel) (2011) 0.83
An ensemble prognostic model for colorectal cancer. PLoS One (2013) 0.82
In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer. J Exp Clin Cancer Res (2014) 0.82
Polyisoprenylated methylated protein methyl esterase is both sensitive to curcumin and overexpressed in colorectal cancer: implications for chemoprevention and treatment. Biomed Res Int (2013) 0.82
A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis. Oncoscience (2014) 0.82
The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther (2015) 0.82
Gene signatures of drug resistance predict patient survival in colorectal cancer. Pharmacogenomics J (2014) 0.82
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol (2010) 0.81
Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Sci Rep (2016) 0.80
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res (2013) 0.80
Relevance of different prior knowledge sources for inferring gene interaction networks. Front Genet (2014) 0.80
Robust prediction of anti-cancer drug sensitivity and sensitivity-specific biomarker. PLoS One (2014) 0.80
Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer (2013) 0.80
CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget (2015) 0.80
Identification of upstream regulators for prognostic expression signature genes in colorectal cancer. BMC Syst Biol (2013) 0.79
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget (2015) 0.78
Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene (2016) 0.78
Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. EBioMedicine (2016) 0.78
VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. Nat Commun (2017) 0.77
Assessment of elasticity of colorectal cancer tissue, clinical utility, pathological and phenotypical relevance. Cancer Sci (2015) 0.77
Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. Oncol Rep (2014) 0.77
Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer. PLoS One (2014) 0.77
Reduced NM23 Protein Level Correlates With Worse Clinicopathologic Features in Colorectal Cancers: A Meta-Analysis of Pooled Data. Medicine (Baltimore) (2016) 0.76
Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers. Mol Clin Oncol (2013) 0.76
Knockdown of CSE1L Gene in Colorectal Cancer Reduces Tumorigenesis in Vitro. Am J Pathol (2016) 0.76
CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation. J Cancer Res Clin Oncol (2015) 0.76
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. EMBO Mol Med (2017) 0.75
Early response index: a statistic to discover potential early stage disease biomarkers. BMC Bioinformatics (2017) 0.75
Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2017) 0.75
Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. Dis Model Mech (2014) 0.75
Aminopeptidase A initiates tumorigenesis and enhances tumor cell stemness via TWIST1 upregulation in colorectal cancer. Oncotarget (2017) 0.75
HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy. Transl Oncol (2016) 0.75
multiClust: An R-package for Identifying Biologically Relevant Clusters in Cancer Transcriptome Profiles. Cancer Inform (2016) 0.75
Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer. Mol Cell Oncol (2015) 0.75
Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. Sci Rep (2016) 0.75
ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients. PeerJ (2016) 0.75
A 19-Gene expression signature as a predictor of survival in colorectal cancer. BMC Med Genomics (2016) 0.75
BEX2 promotes tumor proliferation in colorectal cancer. Int J Biol Sci (2017) 0.75
Building personalized treatment plans for early-stage colorectal cancer patients. Oncotarget (2017) 0.75
Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. Oncogene (2017) 0.75
SIX4 promotes metastasis via activation of the PI3K-AKT pathway in colorectal cancer. PeerJ (2017) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res (1999) 40.62
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Understanding interobserver agreement: the kappa statistic. Fam Med (2005) 22.77
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev (2008) 2.60
Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol (2006) 2.49
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum (1997) 2.22
Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol (2004) 1.89
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res (2007) 1.89
Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer (2007) 1.85
Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol (2008) 1.61
Osteopontin: possible role in prostate cancer progression. Clin Cancer Res (1999) 1.57
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology (2005) 1.56
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res (2007) 1.53
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology (2009) 1.52
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
Survival and the immune response in patients with carcinoma of the colorectum. Gut (1979) 1.12
The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol (2007) 1.03
A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer (2003) 0.98
International network of cancer genome projects. Nature (2010) 20.35
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. BMJ (2004) 7.01
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care (2006) 6.25
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 6.20
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet (2007) 6.02
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med (2003) 4.88
Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol (2002) 4.67
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res (2008) 4.20
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res (2004) 3.76
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem (2006) 3.15
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care (2011) 2.83
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res (2009) 2.80
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol (2007) 2.70
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol (2006) 2.66
Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med (2013) 2.65
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science (2012) 2.58
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol (2011) 2.45
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol (2007) 2.41
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut (2010) 2.30
Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging (2006) 2.26
A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer (2003) 2.26
Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics (2008) 2.24
Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science (2006) 2.24
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat (2005) 2.23
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst (2009) 2.16
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev (2008) 2.00
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis (2006) 1.99
Gene expression in colorectal cancer. Cancer Res (2002) 1.98
Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology (2005) 1.93